Exactly. NeoTrade seems like a paid stooge here. He claims to know that promoters are being called by Private Equity players and investors who are ready to buy at 140-147 band even though they can buy a huge quantity 115-126 range easily. How come being a retail investor he will have knowledge of this things. Phekne ki bhi limit hoti hai yaar.
The breakup of the issue is on the following lines...50% for Qib,15% for Hni and 35% for Retail. Thus for retail it comes to 77 lac shares ,out of that 10% are reserved for Biocon shareholders.So The net portion for retail is 55 lac.So only 90,000 applications of 60 shares will be sufficient to fully subscribe the retail part.Thus it may be preferable to apply in minimum or 1 lot (60 shares). Experts are yet to join .
Request, once again to boarders,,PL.recheck the comment after typing, and correct it,wherever needed,before pressing the Post Comment button.Sometimes,comments are posted in a hurry and they do not make any sense,or become difficult to comprehend.
However, if we annualized these earnings and attribute to its post IPO equity then asking price is at a P/E of 85 and is at a P/BV of 6 plus making it aggressively priced offer. Although it has no listed peers and is the first to go for listing with this kind of business module, it might attract fancy, but based on its pricing, it appears to be “High Risk/Low return” bet. Management has claimed that there are very few organized players in this segment that is growing at rate of 20% plus annually and MBL has a minor market share hence it hopes for bright prospects going forward. This IPO’s BRLMs’ mandates have mixed trends on performance post listing. THESE ARE THE COMMENTS OF DILIP DEVDA AND I FULLY AGREE WITH THIS.COPY PASTED FOR READERS BENEFIT.